slm9 Antibody

Introduction to SKM9-2

SKM9-2 is a human monoclonal antibody engineered to target mesothelioma, a rare cancer associated with asbestos exposure. It was developed by isolating mesothelioma-specific post-translational modifications, particularly sialylated glycans, to achieve high specificity . Unlike conventional markers, SKM9-2 recognizes a novel mucin-like membrane protein, HEG1 (Hypermethylated in Embryonic Genes 1), which is heavily glycosylated .

Mechanism of Action

• Epitope Recognition: SKM9-2 binds to a unique region of the HEG1 protein modified by sialylated O-type glycans. Structural analysis revealed a deep groove in its antigen-binding fragment (Fab) that simultaneously recognizes two glycans and a peptide motif .

• Target Engagement: The antibody exhibits low cross-reactivity to healthy tissues, making it suitable for targeted therapies such as antibody-drug conjugates (ADCs) or radionuclide conjugates .

Preclinical Studies

Therapeutic Applications

SKM9-2 is being explored for:

• Diagnosis: High sensitivity/specificity in detecting mesothelioma via imaging or biopsy .

• Therapy:

  • ADCs: Conjugation with cytotoxic payloads for targeted killing of cancer cells .

  • Immunotherapy: Activation of antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) .

Development Status

• Preclinical Phase: Completed validation studies confirming specificity and efficacy in mesothelioma models .

• Clinical Trials: No publicly disclosed Phase 1/2 trials as of 2025, though its potential as a seed antibody for next-generation therapies remains high .